US EditionWageningen-based Scope Biosciences lands fresh capital to advance CRISPR-based molecular diagnostics platform - Silicon Canals
Summary by Silicon Canals
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Wageningen-based Scope Biosciences lands fresh capital to advance CRISPR-based molecular diagnostics platform - Silicon Canals
Scope Biosciences, a deep tech spin-off from Wageningen University & Research, has secured a follow-on investment from SHIFT Invest and Oost NL to advance its CRISPR-based molecular diagnostics platform. Founded by CEO Niek Savelkoul and headquartered in Wageningen, the Netherlands, Scope Biosciences has now raised a total of €6M in seed-stage funding, combining strategic and venture capital investments with non-dilutive support from leading Eur…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
